Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Vibriolysin is a thermostable zinc metalloprotease enzyme secreted by the marine microorganism *Vibrio proteolyticus* and related species[1][4][6]. It preferentially cleaves peptide bonds with bulky hydrophobic groups in P2 and P1' positions—most notably favoring phenylalanine at P1'[4]. Vibriolysin is under investigation as an enzymatic debridement agent for burn wound eschar; it selectively hydrolyzes denatured proteins such as fibrin, elastin, and collagen in necrotic tissue while sparing viable tissue[1][3]. This selectivity allows for rapid removal of dead tissue without causing bleeding or damaging healthy cells[3]. The enzyme has also been studied for its role in bacterial pathogenicity (notably in cholera), but its primary pharmaceutical application is topical use for burns and burn infections[3][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on vibriolysin.